Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is widely used in patients with type 2 diabetes. However, the pleiotropic effects of sitagliptin is not well understood. OBJECTIVE: To assess the clinical efficacy and safety of sitagliptin on atherosclerosis, β-cell function, and glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsurutani, Yuya, Omura, Masao, Matsuzawa, Yoko, Saito, Jun, Higa, Mariko, Taniyama, Matsuo, Nishikawa, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522982/
https://www.ncbi.nlm.nih.gov/pubmed/28761576
http://dx.doi.org/10.1016/j.curtheres.2016.12.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522982/
https://www.ncbi.nlm.nih.gov/pubmed/28761576
http://dx.doi.org/10.1016/j.curtheres.2016.12.002

Ejemplares similares